Dr. Martens plc (LON:DOCS - Get Free Report) was up 18% on Thursday . The company traded as high as GBX 74.30 ($1.01) and last traded at GBX 70.75 ($0.96). Approximately 6,163,005 shares were traded during trading, an increase of 176% from the average daily volume of 2,233,193 shares. The stock had previously closed at GBX 59.95 ($0.81).
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada lowered their target price on Dr. Martens from GBX 7,000 ($94.75) to GBX 6,000 ($81.21) and set a "sector perform" rating on the stock in a research note on Monday, May 19th.
Check Out Our Latest Analysis on DOCS
Dr. Martens Stock Performance
The company has a market cap of £795.54 million, a P/E ratio of 11.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The stock has a 50 day moving average price of GBX 55.34 and a two-hundred day moving average price of GBX 62.91.
Dr. Martens (LON:DOCS - Get Free Report) last posted its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 ($0.03) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, research analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.
Dr. Martens Cuts Dividend
The business also recently disclosed a dividend, which was paid on Tuesday, April 8th. Shareholders of record on Thursday, March 6th were paid a dividend of GBX 0.85 ($0.01) per share. The ex-dividend date of this dividend was Thursday, March 6th. This represents a yield of 1.47%. Dr. Martens's dividend payout ratio (DPR) is presently 42.53%.
Insiders Place Their Bets
In related news, insider Giles Wilson acquired 32,640 shares of the stock in a transaction on Tuesday, March 25th. The shares were purchased at an average price of GBX 54 ($0.73) per share, for a total transaction of £17,625.60 ($23,857.07). Insiders have purchased a total of 33,206 shares of company stock worth $1,792,771 in the last 90 days. Company insiders own 4.36% of the company's stock.
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Further Reading
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
